Smith & Nephew plc  

(Public, LON:SN)   Watch this stock  
Find more results for SN
1,041.21
-8.79 (-0.84%)
Dec 17 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,032.00 - 1,060.00
52 week 834.00 - 1,198.00
Open 1,044.00
Vol / Avg. 2.37M/2.67M
Mkt cap 9.24B*
P/E 29.27
Div/yield 6.82/1.63*
EPS 0.36*
Shares 893.33M
Beta     -
Inst. own     -
*GBP
Feb 2, 2015
Q4 2014 Smith & Nephew Earnings Release (Estimated) Add to calendar
Dec 4, 2014
Smith & Nephew PLC at Berenberg European Conference
Nov 11, 2014
Smith & Nephew PLC Capital Markets Event
Oct 30, 2014
Q3 2014 Smith & Nephew PLC Earnings Call
Oct 30, 2014
Q3 2014 Smith & Nephew Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 8.89% 12.78%
Operating margin 13.76% 18.62%
EBITD margin - 30.41%
Return on average assets 5.32% 9.70%
Return on average equity 10.01% 14.02%
Employees 14,000 -
CDP Score - 92 B

Address

15 Adam Street
LONDON, ENG WC2N 6LA
United Kingdom - Map
+44-20-74017646 (Phone)
+44-20-79303353 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management. It operates on a worldwide basis and has distribution channels in over 90 countries. Orthopaedic reconstruction implants include hip, knee and shoulder joints, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. Endoscopy business develops and commercialises endoscopic (minimally invasive surgery) techniques, educational programmes and services. Advanced Wound Management business offers a range of products from initial wound bed preparation through to full wound closure. In May 2012, it acquired Kalypto Medical, Inc. In May 2014, the Company acquired ArthroCare Corporation.

Officers and directors

Olivier Bohuon Chief Executive Officer, Executive Director
Age: 55
Julie Brown Chief Financial Officer, Executive Director
Age: 51
Rodrigo Bianchi President, IRAMEA
Age: 54
Michael G. Frazzette President - Advanced Surgical Devices
Age: 52
R. Gordon Howe President - Global Operations
Age: 51
Roger Teasdale President - Advanced Wound Management
Age: 46
Francisco Canal Vega President - Latin America
Age: 52
John W. Campo Chief Legal Officer
Age: 59
Helen Maye Chief Human Resources Officer
Age: 54
Cyrille Petit Chief Corporate Development Officer
Age: 43